Investing.com - Financial Markets Worldwide

Teva Pharma Industries Ltd ADR (TEVA)

NYSE
Symbol
Exchange
Currency
TEVANYSEUSD
TEVANMexicoMXN
TEVAyTradeGateEUR
TEVATel AvivILS
T1EV34B3BRL
TEVAgViennaEUR
Currency in USD
16.23
-0.06(-0.37%)
Closed
After Hours
16.24+0.01(+0.06%)

TEVA Comments

Are you guys buying now or do you believe the stock will fall much lower then this?
I think it is good price for buying below 17$. I am holding
back above fib level 38,2% retracement
Wtf???
Overacting
Now Teva at 17.35$, IMO it will get to 21$ in the next month. so I recommend buying now.
IMO we can visit today 20.20$. But I think it will go back up pretty fast.
Not a bad day ... 26.47%, in 1-2 years we are at 30$. 1-2 years we are at 30$.
Teva now 16.81, good price for buying.
Now above 19$ ... told ya
19.84
21$
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
New price target of 26$ the other day
Price targets and ER delayed response, now 18.5$
Glen Santangelo from Jefferies, Buy, 23$
All new price targets are buy and above 20$-21$
Post er the average of the new price targets is 19$ Nice. This will continue all the way to 30, 40$.
One day to ER of Q1
New price target of 17$ by Barclays analyst
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
1% on a Friday with 9.13M volume someone is buying.
simple story of debt reduction and value going up. revenue growth will set the pace will move up in the next 2-3 years to about 30-40$
long trend starting
hopefully ! Ive been w8ing for it for 3 y xD
11,40 will hold as celling or convert to floor :)?
looking good on pre-market. Wonder how USA downgrade might spoil the fun here
25 next year seems quite doable
Somebody know the consensus for Q2 today ?
first real report of new CEO... it will be interesting
OKE
...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.